Everything below concerns circadian rhythm. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
Henriksen was working with potter Joan Stone doing his pottery in her studio during the early 1970s. Henriksen has been married twice. He was married to Mary Jane Evans from 1985 to 1989 and to Jane Pollack from 1995 to 2006. Henriksen has one child from each marriage.
=== Physical Response === When exposed to ultrasound, microbubbles oscillate in response to the incoming pressure waves in one of two ways. With lower pressures, higher frequencies, and larger microbubble diameter, microbubbles oscillate, or cavitate, stably. This causes microstreaming near the surrounding vasculature and tissues, inducing shear stresses that can create pores on the endothelial layer. This pore formation enhances endocytosis and permeability. At lower frequencies, higher pressures, and lower microbubble diameter, microbubbles oscillate inertially; they expand and contract violently, ultimately leading to microbubble collapse. This phenomenon can create mechanical stresses and microjets along the vascular wall, which has been shown to disrupt tight cellular junctions as well as induce cellular permeability. Extremely high pressures cause small vessel destruction, but the pressure can be tuned to only create transient pores in vivo. microbubble destruction serves as a desirable method for drug delivery vehicles. The resulting force from destruction can dislodge the therapeutic payload present on the microbubble and simultaneously sensitize the surrounding cells for drug uptake.
== See also == Best practice, a method or technique that has been generally accepted as superior to alternatives because it tends to produce superior results European Medicines Agency (EMA), European Union agency evaluating and supervising pharmaceutical products Food and Drug Administration (FDA), a United States Food federal agency protecting and promoting public health through the control and supervision International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), initiative to bring together regulatory authorities and pharmaceutical industry Organisation for Economic Co-operation and Development (OECD), intergovernmental organisation for stimulating economic progress and world trade through democracy, market economy, and good practices Pride of workmanship, sense of having done good work, an element of job satisfaction Validation (drug manufacture), a documented process to ensure a product meets its required specifications and quality
Pyrolysis is the basis of several methods for producing fuel from biomass, i.e. lignocellulosic biomass. Crops studied as biomass feedstock for pyrolysis include native North American prairie grasses such as switchgrass and bred versions of other grasses such as Miscantheus giganteus. Other sources of organic matter as feedstock for pyrolysis include greenwaste, sawdust, waste wood, leaves, vegetables, nut shells, straw, cotton trash, rice hulls, and orange peels. Animal waste including poultry litter, dairy manure, and potentially other manures are also under evaluation. Some industrial byproducts are also suitable feedstock including paper sludge, distillers grain, and sewage sludge. In the biomass components, the pyrolysis of hemicellulose happens between 210 and 310 °C. The pyrolysis of cellulose starts from 300 to 315 °C and ends at 360–380 °C, with a peak at 342–354 °C. Lignin starts to decompose at about 200 °C and continues until 1000 °C. Synthetic diesel fuel by pyrolysis of organic materials is not yet economically competitive. Higher efficiency is sometimes achieved by flash pyrolysis, in which finely divided feedstock is quickly heated to between 350 and 500 °C (660 and 930 °F) for less than two seconds. Syngas is usually produced by pyrolysis. The low quality of oils produced through pyrolysis can be improved by physical and chemical processes, which might drive up production costs, but may make sense economically as circumstances change.
Sources: en.wikipedia.org
Eating much faster than normal, perhaps in a short space of time Eating until feeling uncomfortably full Eating a large amount even when not hungry Subjective loss of control over how much or what is eaten Planning and allocating specific times for bingeing Eating alone or secretly Not being able to remember what was eaten after the binge Feelings of guilt, shame, or disgust following a food binge Body image disturbance In contrast to bulimia nervosa, binge eating episodes are not regularly followed by activities intended to compensate for the amount of food consumed, such as self-induced vomiting, laxative or enema misuse, or strenuous exercise. BED is characterized more by overeating than dietary restriction. Those with BED often have poor body image and frequently diet, but are unsuccessful due to the severity of their binge eating. Obesity is common in persons with BED, as are depression, low self-esteem, stress and boredom. Regarding cognitive abilities, individuals showing severe binge eating symptoms may experience small dysfunctions in executive functions. Those with BED are also at risk of non-alcoholic fatty liver disease, menstrual irregularities such as amenorrhea, and gastrointestinal problems such as acid reflux and heartburn.
== K == K-complex A large, slow wave seen in EEG during stage 2 of non-REM sleep. It is involved in memory consolidation and sensory processing during sleep. Kainate receptor A subtype of ionotropic glutamate receptor involved in fast excitatory synaptic transmission. Kainate receptors play roles in learning and are implicated in seizure disorders. Kallmann syndrome A genetic condition characterized by delayed or absent puberty and an impaired sense of smell. It results from disrupted migration of olfactory and gonadotropin-releasing hormone neurons. Karyokinesis The process of nuclear division during cell division. In the context of developmental neuroscience, it describes how neural progenitor cells divide in the developing brain. Karyotype A visual profile of an organism’s chromosomes. In neuroscience, used in research or diagnostics for identifying chromosomal abnormalities linked to neurodevelopmental disorders. Kelvin–Voigt model A viscoelastic model used in computational neuroscience and biomechanics to describe tissue deformation, including brain tissue mechanics. Keratitis Inflammation of the cornea, which may be linked to neural dysfunction in the trigeminal nerve or autonomic nervous system regulation. Kinesthesia The sense of limb and body movement, closely related to proprioception. It is mediated by mechanoreceptors in muscles and joints and processed in the somatosensory cortex. Kindling A process by which repeated sub-threshold electrical or chemical stimulation of the brain leads to progressively more intense seizures. Used as a model for epilepsy.
Abortive initiation, the unproductive cycling of RNA polymerase before the promoter escape transition, results in short RNA fragments of around 9 bp in a process known as abortive transcription. The extent of abortive initiation depends on the presence of transcription factors and the strength of the promoter contacts.
In Germany, dihydrocodeine has been used off-label in OAT for many years, however it is no longer frequently prescribed for this purpose. Extended-release dihydrocodeine is again in current use in Austria for this reason. Research into the usefulness of piritramide, extended-release hydromorphone (including polymer implants lasting up to 90 days), dihydroetorphine and other substances for OAT is at various stages in a number of countries. In 2020 in Vancouver, Canada, health authorities began vending machine dispensing of hydromorphone tablets as a response to elevated rates of fatal overdose from street drugs contaminated with fentanyl and fentanyl analogues. In some countries (not the US, UK, Canada, or Australia), regulations enforce a limited time period for people on OAT/OST programs that conclude when a stable economic and psychosocial situation is achieved. (Patients with HIV/AIDS or hepatitis C are usually excluded from this requirement.) In practice, 40–65% of patients maintain complete abstinence from opioids while receiving opioid agonist therapy, and 70–95% are able to reduce their use significantly, while experiencing a concurrent elimination or reduction in medical (improper diluents, non-sterile injecting equipment), psychosocial (mental health, relationships), and legal (arrest and imprisonment) issues that can arise from the use of illicit opioids. OAT/OST outlets in some settings also offer basic primary health care.
=== Use in exercise and sports === Pseudoephedrine has been used as a performance-enhancing drug in exercise and sports due to its sympathomimetic and stimulant effects. Because of these effects, pseudoephedrine can increase heart rate, elevate blood pressure, improve mental energy, and reduce fatigue, among other performance-enhancing effects. A 2015 systematic review found that pseudoephedrine lacked performance-enhancing effects at therapeutic doses (60–120 mg) but significantly enhanced athletic performance at supratherapeutic doses (≥180 mg). A subsequent 2018 meta-analysis, which included seven additional studies, found that pseudoephedrine had a small positive effect on heart rate (SMDTooltip standardized mean difference = 0.43) but insignificant effects on time trials, perceived exertion ratings, blood glucose levels, and blood lactate levels. However, subgroup analyses revealed that effect sizes were larger for heart rate increases and quicker time trials in well-trained athletes and younger participants, for shorter exercise sessions with pseudoephedrine administered within 90 minutes beforehand, and with higher doses of pseudoephedrine. A dose–response relationship was established, with larger doses (>170 mg) showing greater increases in heart rate and faster time trials than with smaller doses (≤170 mg) (SMD = 0.85 for heart rate and SMD = -0.24 for time trials, respectively). In any case, the meta-analysis concluded that the performance-enhancing effects of pseudoephedrine were marginal to small and likely to be lower in magnitude than with caffeine.
Sources: en.wikipedia.org
=== Treatment === It has been suggested that chelation agents, such as British anti-Lewisite (dimercaprol), can be used to decontaminate humans. In one experiment, rats were given a fatal dose of 1.45 MBq/kg (8.7 ng/kg) of 210Po; all untreated rats were dead after 44 days, but 90% of the rats treated with the chelation agent HOEtTTC remained alive for five months.
== Research == In a March 2020 phase II clinical trial, Stone and colleagues suggested that phenelzine's potential effectiveness on treatment of prostate cancer. Some animal trials have shown phenelzine to potentially have neuroprotective effects.
=== Bodyplans === Swimming animals including fish such as herrings, marine mammals such as dolphins, and ichthyosaurs (of the Mesozoic) all converged on the same streamlined shape. A similar shape and swimming adaptations are even present in molluscs, such as Phylliroe. The fusiform bodyshape (a tube tapered at both ends) adopted by many aquatic animals is an adaptation to enable them to travel at high speed in a high drag environment. Similar body shapes are found in the earless seals and the eared seals: they still have four legs, but these are strongly modified for swimming. The marsupial fauna of Australia and the placental mammals of the Old World have several strikingly similar forms, developed in two clades, isolated from each other. The body, and especially the skull shape, of the thylacine (Tasmanian tiger or Tasmanian wolf) converged with those of Canidae such as the red fox, Vulpes vulpes.
== Background == Ronald Charles Beavis was born in Winnipeg, Manitoba in May 1958. He went to school in Winnipeg and became interested in science at an early age. As a high school student he participated in the Manitoba Science Fair for projects related to chemistry and physics. He received a B.Sc. (Hons) in Zoology and Physics and a Ph.D. (Physics) from the University of Manitoba.
Blood tests conducted by WADA at the 2004 Olympic Games in Athens, Greece, targeted primarily HGH. Use of the drug for performance enhancement is not currently approved by the FDA. GH has been studied for use in raising livestock more efficiently in industrial agriculture and several efforts have been made to obtain governmental approval to use GH in livestock production. These uses have been controversial. In the United States, the only FDA-approved use of GH for livestock is the use of a cow-specific form of GH called bovine somatotropin for increasing milk production in dairy cows. Retailers are permitted to label containers of milk as produced with or without bovine somatotropin.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.